Gemina Laboratories Ltd.
GLAB
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.70K | 7.70K | 7.70K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.70K | 7.70K | 7.70K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.70K | 7.70K | 7.70K | -- | -- |
| SG&A Expenses | 1.44M | 1.61M | 1.78M | 1.90M | 1.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.02M | 2.38M | 2.74M | 2.83M | 2.61M |
| Operating Income | -2.01M | -2.37M | -2.73M | -2.83M | -2.61M |
| Income Before Tax | -2.08M | -2.47M | -2.87M | -2.94M | -2.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.08 | -2.47 | -2.87 | -2.94 | -2.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.08M | -2.47M | -2.87M | -2.94M | -2.51M |
| EBIT | -2.01M | -2.37M | -2.73M | -2.83M | -2.61M |
| EBITDA | -2.01M | -2.32M | -2.67M | -2.76M | -2.55M |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 304.33M | 302.27M | 299.24M | 296.16M | 296.43M |
| Average Diluted Shares Outstanding | 304.33M | 302.27M | 299.24M | 296.16M | 296.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |